Understanding and targeting specific mutations in a type of breast cancer
Characterizing and Targeting ERBB2 Mutations in Invasive Lobular Carcinoma
This study is looking at a specific type of breast cancer called invasive lobular carcinoma to see how certain gene changes might affect treatment, with the goal of finding better, personalized therapies for patients like you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10893353 on NIH RePORTER |
What this research studies
This research focuses on invasive lobular carcinoma (ILC), a less-studied form of breast cancer that often has different characteristics compared to more common types. The study aims to investigate specific mutations in the ERBB2 gene that are found in ILC and how these mutations affect treatment outcomes. By using advanced techniques like CRISPR for genome editing and analyzing blood samples, the researchers hope to identify effective combination therapies for patients with these mutations. This could lead to more personalized treatment options for individuals diagnosed with ILC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with invasive lobular carcinoma, particularly those with ERBB2 mutations.
Not a fit: Patients with other types of breast cancer or those without ERBB2 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments specifically tailored for patients with ERBB2 mutant invasive lobular carcinoma.
How similar studies have performed: Other research has shown promising results with targeted therapies for similar mutations in breast cancer, indicating potential for success in this area.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Liu, Jie Bin — University of Pittsburgh at Pittsburgh
- Study coordinator: Liu, Jie Bin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.